Ryvu Therapeutics filings
Current reports and announcements from Ryvu Therapeutics (RVU), newest first. Filings published on the company's investor-relations site carry a short AI summary based only on the filing text.
- Dane przedkliniczne in vivo dla RVU602 – nowej substancji czynnej do ADC – zaprezentowane podczas World ADC Congress 2026 / Preclinical in-vivo data for RVU602, a novel ADC payload, presented at the World ADC Congress 2026
FilingParkiet
- Uruchomienie przez Ryvu wyspecjalizowanego biznesu usługowego w obszarze wczesnego rozwoju klinicznego pod marką „Keelira” / Ryvu launches a specialized early clinical development services business under the “Keelira” brand
FilingParkiet
- Rekomendowanie projektu Ryvu do dofinansowania przez Narodowe Centrum Badań i Rozwoju / Ryvu’s project recommended for funding by the National Centre for Research and Development
FilingParkiet
This information is provided for informational purposes only and does not constitute investment advice or a recommendation. Listings describe companies by the stated criteria and are not an inducement to buy or sell any financial instrument. Verify figures against official sources before making any investment decision.